Table Of Content:
CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Inhalable Drugs
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Inhalable Drugs Market By Type
1.2.2.1. Global Inhalable Drugs Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.2.2. Global Inhalable Drugs Market Revenue Share By Type in 2018
1.2.2.3. Suspension Aerosol
1.2.2.4. Solution Aerosol
1.2.2.5. Dry Powder Formulation
1.2.3. Inhalable Drugs Market By Application
1.2.3.1. Global Inhalable Drugs Market Revenue and Growth Rate Comparison By Application (2015-2026)
1.2.3.2. Global Inhalable Drugs Market Revenue Share By Application in 2018
1.2.3.3. Respiratory diseases
1.2.3.3.1. Asthma
1.2.3.3.2. Chronic Obstructive Pulmonary Disease (COPD)
1.2.3.3.3. Infectious Diseases
1.2.3.3.4. Other respiratory diseases
1.2.3.4. Non-respiratory diseases
1.2.4. Inhalable Drugs Market By Geography
1.2.4.1. Global Inhalable Drugs Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.4.2. North America Inhalable Drugs Market Revenue and Growth Rate (2015-2026)
1.2.4.3. Europe Inhalable Drugs Market Revenue and Growth Rate (2015-2026)
1.2.4.4. Asia-Pacific Inhalable Drugs Market Revenue and Growth Rate (2015-2026)
1.2.4.5. Latin America Inhalable Drugs Market Revenue and Growth Rate (2015-2026)
1.2.4.6. Middle East and Africa (MEA) Inhalable Drugs Market Revenue and Growth Rate (2015-2026)
CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2018
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players
CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Inhalable Drugs Major Manufacturers in 2018
3.2. Manufacturing Plants Distribution of Global Inhalable Drugs Major Manufacturers in 2018
3.3. R&D Status and Technology Source of Global Inhalable Drugs Major Manufacturers in 2018
3.4. Raw Materials Sources Analysis of Global Inhalable Drugs Major Manufacturers in 2018
CHAPTER 4. INHALABLE DRUGS MARKET BY TYPE
4.1. Global Inhalable Drugs Revenue By Type
4.2. Suspension Aerosol
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Solution Aerosol
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Dry Powder Formulation
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 5. INHALABLE DRUGS MARKET BY APPLICATION
5.1. Global Inhalable Drugs Revenue By Application
5.2. Respiratory diseases
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.2.3. Asthma
5.2.4. Chronic Obstructive Pulmonary Disease (COPD)
5.2.5. Infectious Diseases
5.2.6. Other respiratory diseases
5.3. Non-respiratory diseases
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 6. NORTH AMERICA INHALABLE DRUGS MARKET BY COUNTRY
6.1. North America Inhalable Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2. North America Inhalable Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
6.3. U.S.
6.3.1. U.S. Inhalable Drugs Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
6.4. Canada
6.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
CHAPTER 7. EUROPE INHALABLE DRUGS MARKET BY COUNTRY
7.1. Europe Inhalable Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. Europe Inhalable Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. UK
7.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.4. Germany
7.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.5. France
7.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.6. Spain
7.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.6.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.7. Rest of Europe
7.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.7.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
CHAPTER 8. ASIA-PACIFIC INHALABLE DRUGS MARKET BY COUNTRY
8.1. Asia-Pacific Inhalable Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Asia-Pacific Inhalable Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. China
8.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.4. Japan
8.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.5. India
8.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.6. Australia
8.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.7. South Korea
8.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.8. Rest of Asia-Pacific
8.8.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.8.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
CHAPTER 9. LATIN AMERICA INHALABLE DRUGS MARKET BY COUNTRY
9.1. Latin America Inhalable Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Latin America Inhalable Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. Brazil
9.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.4. Mexico
9.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.5. Rest of Latin America
9.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
CHAPTER 10. MIDDLE EAST & AFRICA INHALABLE DRUGS MARKET BY COUNTRY
10.1. Middle East & Africa Inhalable Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Middle East & Africa Inhalable Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. GCC
10.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.4. South Africa
10.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.5. Rest of Middle East & Africa
10.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
CHAPTER 11. COMPANY PROFILE
11.1. AstraZeneca
11.1.1. Company Snapshot
11.1.2. Overview
11.1.3. Financial Overview
11.1.4. Product Portfolio
11.1.5. Key Developments
11.1.6. Strategies
11.2. Sanofi
11.2.1. Company Snapshot
11.2.2. Overview
11.2.3. Financial Overview
11.2.4. Product Portfolio
11.2.5. Key Developments
11.2.6. Strategies
11.3. Vectura
11.3.1. Company Snapshot
11.3.2. Overview
11.3.3. Financial Overview
11.3.4. Product Portfolio
11.3.5. Key Developments
11.3.6. Strategies
11.4. Mylan
11.4.1. Company Snapshot
11.4.2. Overview
11.4.3. Financial Overview
11.4.4. Product Portfolio
11.4.5. Key Developments
11.4.6. Strategies
11.5. GlaxoSmithKline
11.5.1. Company Snapshot
11.5.2. Overview
11.5.3. Financial Overview
11.5.4. Product Portfolio
11.5.5. Key Developments
11.5.6. Strategies
11.6. Mundipharma
11.6.1. Company Snapshot
11.6.2. Overview
11.6.3. Financial Overview
11.6.4. Product Portfolio
11.6.5. Key Developments
11.6.6. Strategies
11.7. Boehringer Ingelheim International GmbH
11.7.1. Company Snapshot
11.7.2. Overview
11.7.3. Financial Overview
11.7.4. Product Portfolio
11.7.5. Key Developments
11.7.6. Strategies
11.8. Cipla Inc.
11.8.1. Company Snapshot
11.8.2. Overview
11.8.3. Financial Overview
11.8.4. Product Portfolio
11.8.5. Key Developments
11.8.6. Strategies
11.9. Others
11.9.1. Company Snapshot
11.9.2. Overview
11.9.3. Financial Overview
11.9.4. Product Portfolio
11.9.5. Key Developments
11.9.6. Strategies
CHAPTER 12. RESEARCH APPROACH
12.1. Research Methodology
12.1.1. Initial Data Search
12.1.2. Secondary Research
12.1.3. Primary Research
12.2. Assumptions and Scope
Inhalable drugs refer to the group of substances that people inhale into the lungs to treat infections or particular diseases.
The rising prevalence of non-respiratory diseases such as Parkinson’s disease and diabetes is main driver of the inhalable drugs market.
Acumen Research and Consulting says that the inhalable drugs market value is anticipated to be worth around US$ 41.5 million in 2026.
The inhalable drugs market is anticipated to grow over 6.4 % CAGR during the forecast period 2019 to 2026.
North America held maximum share in 2018 for inhalable drugs market.
Asia Pacific is projected to grow at a fast pace during forecast period in the inhalable drugs market.
AstraZeneca, Sanofi, Vectura, Mylan, GlaxoSmithKline, Mundipharma, Boehringer Ingelheim International GmbH, and Cipla Inc. are the key players operating in the inhalable drugs market.
Customer Satisfaction
Availability - we are always there when you need us
Fortune 50 Companies trust Acumen Research and Consulting
of our reports are exclusive and first in the industry
more data and analysis
reports published till date